跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

QCRBNSET

Sigma-Aldrich

QuicTPD CRBN ligand Set

new
登录查看公司和协议定价


About This Item

包装

pkg of 50 mg

质量水平

储存温度

2-8°C

一般描述

5-Amino Thalidomide, Lenalidomide, Pomalidomide and C-5 Lenalidomide are recruiters of CRBN protein that can be leveraged for targeted protein degradation research. They are provided at 50 mg each.

应用

Useful for construction of CRBN based partial protacs of full protacs, by utilizing the amine terminus to add suitable linkers with peptide coupling reactions. These can also be used as controls/competitors to confirm target engagement of putative protacs.

特点和优势

Quantities provided are sufficient to do atleast 96 reactions at 2 micromole each with a D2B approach with a library of suitable bifunctional linkers ending in carboxylic acid terminus to generate a library of partial protacs or full protacs.

其他说明

CRBN Ligand Set part of QuicTPD kit

相关产品

产品编号
说明
价格

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A - STOT RE 2

靶器官

Blood

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Aleša Bricelj et al.
ACS medicinal chemistry letters, 12(11), 1733-1738 (2021-11-20)
Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This
Alexandru D Buhimschi et al.
Biochemistry, 57(26), 3564-3575 (2018-06-01)
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine
Georg E Winter et al.
Science (New York, N.Y.), 348(6241), 1376-1381 (2015-05-23)
The development of effective pharmacological inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem. In part, this is because many small-molecule antagonists disrupt the activity of only one domain in the target protein. We devised a
Gang Lu et al.
Science (New York, N.Y.), 343(6168), 305-309 (2013-12-03)
Thalidomide-like drugs such as lenalidomide are clinically important treatments for multiple myeloma and show promise for other B cell malignancies. The biochemical mechanisms underlying their antitumor activity are unknown. Thalidomide was recently shown to bind to, and inhibit, the cereblon

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门